Vanguard Group
INDV icon

Vanguard Group’s Indivior Pharmaceuticals INDV Stock Holding History

Vanguard Group’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$196M Buy
5,473,891
+2,008,078
+58% +$61.3M ﹤0.01% 1556
2025
Q3 		$83.1M Sell
3,465,813
-2,181,496
-39% -$45.7M ﹤0.01% 1938
2025
Q2 		$83.9M Buy
5,647,309
+1,016,088
+22% +$11.8M ﹤0.01% 1902
2025
Q1 		$43.8M Buy
4,631,221
+71,539
+2% +$752K ﹤0.01% 2148
2024
Q4 		$58.4M Sell
4,559,682
-144,104
-3% -$1.48M ﹤0.01% 2102
2024
Q3 		$46.4M Buy
4,703,786
+33,251
+0.7% +$389K ﹤0.01% 2213
2024
Q2 		$75.3M Sell
4,670,535
-1,241,181
-21% -$22.4M ﹤0.01% 1972
2024
Q1 		$127M Buy
5,911,716
+12,526
+0.2% +$235K ﹤0.01% 1745
2023
Q4 		$90.1M Buy
5,899,190
+52,836
+0.9% +$938K ﹤0.01% 1917
2023
Q3 		$135M Buy
5,846,354
+90,673
+2% +$2.07M ﹤0.01% 1644
2023
Q2 		$137M Buy
+5,755,681
New +$132M ﹤0.01% 1677

Other funds holding INDV

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCM
Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group's INDV Position: Q4 2025 in Review

Vanguard Group increased its Indivior Pharmaceuticals (INDV) stake by 58% in Q4 2025, buying an estimated $61.3M and bringing the position to 5,473,891 shares worth $196M. The position accounts for ﹤0.01% of the portfolio, ranked #1556.

Vanguard Group first reported a position in INDV in Q2 2023 and has held it in 11 quarters since. 259 funds tracked by Wall St. Rank hold INDV as of Q4 2025.

  • Vanguard Group held 5,473,891 shares of Indivior Pharmaceuticals worth $196M as of Q4 2025.
  • Vanguard Group bought 2,008,078 Indivior Pharmaceuticals shares in Q4 2025, an estimated $61.3M.
  • Indivior Pharmaceuticals made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #1556 holding.
  • Vanguard Group first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 11 quarters since.
  • 259 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.